QUIT-LIKE-SWEDEN
29.5.2024 14:22:31 CEST | Business Wire | Press release
Millions of lives could be saved with a more progressive approach to tobacco control measures, says a new platform committed to encouraging countries to follow the Swedish Experience and become ‘smoke-free’. As the world gears up to observe World No Tobacco Day (WNTD) on May 31, Quit Like Sweden, launched earlier this year in Brazil, is calling for proven strategies to enhance the global fight against smoking.
Traditionally, WNTD has been marked exclusively by calls for the complete abandonment of smoking. However, Quit Like Sweden argues that it's time for policymakers, regulators, governments, the media, and the general public to engage in a meaningful discussion about the strategies that do reduce the devastating impacts of smoking and smoking-related illnesses.
Suely Castro, Founder of Quit Like Sweden, emphasized the need for a new approach, citing the Swedish Experience and remarkable progress in tobacco control.
"Each World No Tobacco Day, the international community argues that a world without cigarettes is the ultimate aim. But this World No Tobacco Day, instead of discussing what could be possible, it’s time to look at what is already being done by the only country that is close to quitting smoking: Sweden," said Suely Castro.
While Sweden has rigorously adopted smoking cessation and prevention measures, it has also enabled smokers to choose safer alternatives. This approach, based on what Ms Castro calls the three A's – which stand for the Accessibility, Acceptability, and Affordability of safer alternatives – has resulted in millions of Swedes choosing to leave cigarettes behind and switch to safer alternatives.
"In Sweden, one in four adults uses nicotine every day. While this is the same level as the rest of Europe, Sweden’s incidence of cancer is 41% lower, and smoking-related deaths in Sweden are less than half of smoking-related deaths in 24 of the other 26 EU countries”, Castro said.
“This is the case within European countries, which have similar regulations to those of Sweden, although not its comprehensive approach to eradicating smoking. Just imagine what the global impact of the full Swedish Experience could be.”
“We have the ability to save millions of lives just by replicating a model that has already worked so well for Sweden,” she said. "And there’s no better time to start that conversation than now.”
Background
Quit Like Sweden is a not-for-profit platform with the aim to encourage countries to take action to replicate the Swedish Experience in a comprehensive strategy that also includes measures and programmes focused on smoking cessation and prevention, and enabling people who smoke to choose alternatives instead.
We don’t advocate for the removal of measures and programmes that contribute to smoking cessation or prevention, and instead appeal to all policymakers in all countries, intergovernmental and non-governmental organizations to complement those measures and programmes.
Sweden Statistics
As a result of Sweden’s progressive tobacco control measures:
- Sweden is the only country in the world to officially be ‘smoke-free’, when its smoking prevalence falls below 5% later this year.
- Across Europe, the smoking rate is 5 times higher than Sweden’s.
- 24 of the 27 EU countries have a tobacco-related mortality rate at least twice as high as Sweden’s.
- Sweden’s incidence of cancer is 41% lower than the rest of Europe’s, which means 38% lower levels of total cancer deaths.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529797728/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
